(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.57%) $79.45
(1.24%) $1.956
(0.74%) $2 328.10
(0.16%) $26.79
(1.20%) $966.40
(0.03%) $0.933
(-0.04%) $11.03
(-0.07%) $0.798
(0.27%) $93.51
-1.98% € 91.40
Live Chart Being Loaded With Signals
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products...
Stats | |
---|---|
Tagesvolumen | 26 806.00 |
Durchschnittsvolumen | 51 037.00 |
Marktkapitalisierung | 406.69B |
EPS | €8.63 ( 2023-06-30 ) |
Last Dividend | €3.00 ( 2023-08-18 ) |
Next Dividend | €0 ( N/A ) |
P/E | 22.91 |
ATR14 | €2.62 (2.86%) |
Volumen Korrelation
Novo Nordisk A/S Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Novo Nordisk A/S Korrelation - Währung/Rohstoff
Novo Nordisk A/S Finanzdaten
Annual | 2022 |
Umsatz: | €176.95B |
Bruttogewinn: | €148.51B (83.92 %) |
EPS: | €24.51 |
FY | 2022 |
Umsatz: | €176.95B |
Bruttogewinn: | €148.51B (83.92 %) |
EPS: | €24.51 |
FY | 2021 |
Umsatz: | €140.80B |
Bruttogewinn: | €117.14B (83.20 %) |
EPS: | €20.79 |
FY | 2020 |
Umsatz: | €126.95B |
Bruttogewinn: | €106.01B (83.51 %) |
EPS: | €18.05 |
Financial Reports:
No articles found.
Novo Nordisk A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€4.25 (N/A) |
€0 (N/A) |
€8.15 (N/A) |
€0 (N/A) |
€3.00 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.670 | 2002-03-13 |
Last Dividend | €3.00 | 2023-08-18 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 30 | -- |
Total Paid Out | €100.58 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.88 | -- |
Div. Sustainability Score | 6.14 | |
Div.Growth Potential Score | 4.38 | |
Div. Directional Score | 5.26 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
UBK.DE | Ex Dividend Junior | 2023-06-30 | Sporadic | 0 | 0.00% | |
DWS.DE | Ex Dividend Knight | 2023-06-16 | Annually | 0 | 0.00% | |
NEM.DE | Ex Dividend Knight | 2023-05-24 | Annually | 0 | 0.00% | |
AAG.DE | Ex Dividend Junior | 2023-06-16 | Sporadic | 0 | 0.00% | |
XTP.F | Ex Dividend Junior | 2023-05-12 | Sporadic | 0 | 0.00% | |
FRE.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
PHI1.DE | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
AWC.DE | Ex Dividend Junior | 2023-08-07 | Quarterly | 0 | 0.00% | |
HRPK.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
SGF.DE | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.351 | 1.500 | 2.98 | 4.47 | [0 - 0.5] |
returnOnAssetsTTM | 0.251 | 1.200 | 1.635 | 1.962 | [0 - 0.3] |
returnOnEquityTTM | 0.869 | 1.500 | 1.460 | 2.19 | [0.1 - 1] |
payoutRatioTTM | 0.422 | -1.000 | 5.78 | -5.78 | [0 - 1] |
currentRatioTTM | 0.824 | 0.800 | -0.880 | -0.704 | [1 - 3] |
quickRatioTTM | 0.635 | 0.800 | -0.971 | -0.777 | [0.8 - 2.5] |
cashRatioTTM | 0.175 | 1.500 | -0.141 | -0.211 | [0.2 - 2] |
debtRatioTTM | 0.0884 | -1.500 | 8.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -18.83 | 1.000 | -8.08 | -8.08 | [3 - 30] |
operatingCashFlowPerShareTTM | 23.78 | 2.00 | 2.07 | 4.15 | [0 - 30] |
freeCashFlowPerShareTTM | 17.38 | 2.00 | 1.308 | 2.62 | [0 - 20] |
debtEquityRatioTTM | 0.285 | -1.500 | 8.86 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.841 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.392 | 1.000 | 4.16 | 4.16 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 4.01 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.715 | 0.800 | 8.57 | 6.85 | [0.5 - 2] |
Total Score | 6.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.52 | 1.000 | 6.01 | 0 | [1 - 100] |
returnOnEquityTTM | 0.869 | 2.50 | 4.51 | 2.19 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 17.38 | 2.00 | 4.21 | 2.62 | [0 - 30] |
dividendYielPercentageTTM | 0.440 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 23.78 | 2.00 | 2.07 | 4.15 | [0 - 30] |
payoutRatioTTM | 0.422 | 1.500 | 5.78 | -5.78 | [0 - 1] |
pegRatioTTM | 0.142 | 1.500 | -2.38 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.496 | 1.000 | 0.0917 | 0 | [0.1 - 0.5] |
Total Score | 4.38 |
Novo Nordisk A/S
Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.